Changqing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Changqing Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alexander S. C. Fraser
Michael Smith Laboratories and Department of Chemistry, University of British Columbia, Vancouver, BC, Canada
1 shared publication - Benjamin Wei‐Qiang Hui
Michael Smith Laboratories and Department of Chemistry, University of British Columbia, Vancouver, BC, Canada
1 shared publication Danisa M. Bescucci
Lethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, AB, Canada
1 shared publication- Deanna Lynn Gibson
Department of Biology, University of British Columbia
1 shared publication - Dennis Wade Abbott
Lethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, AB, Canada.
1 shared publication - Eric C. Martens
Department of Microbiology and Immunology, University of Michigan, Ann Arbor, USA
1 shared publication
Latest Publications
- 26 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6754) , 1410-1416
Bespoke plant glycoconjugates for gut microbiota–mediated drug targeting
The gut microbiota of mammals possess distinctive metabolic pathways with untapped therapeutic potential. Using molecular insights into dietary fiber metabolism by the human gut microbiota, we designed a targeted drug delivery system, called GlycoCaging, that is based on bespoke glycoconjugates of a complex plant oligosaccharide. GlycoCaging of exemplar anti-inflammatory drugs enabled release of active molecules triggered by specific glycosidases of autochthonous gut bacteria. GlycoCaging ensured that drug efficacy was potentiated, and off-target effects were eliminated in murine models of inflammatory bowel disease. Biochemical and metagenomic analyses of gut microbiota of individual humans confirmed the broad applicability of this strategy.
- 26 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6754) , 1410-1416
Bespoke plant glycoconjugates for gut microbiota–mediated drug targeting
The gut microbiota of mammals possess distinctive metabolic pathways with untapped therapeutic potential. Using molecular insights into dietary fiber metabolism by the human gut microbiota, we designed a targeted drug delivery system, called GlycoCaging, that is based on bespoke glycoconjugates of a complex plant oligosaccharide. GlycoCaging of exemplar anti-inflammatory drugs enabled release of active molecules triggered by specific glycosidases of autochthonous gut bacteria. GlycoCaging ensured that drug efficacy was potentiated, and off-target effects were eliminated in murine models of inflammatory bowel disease. Biochemical and metagenomic analyses of gut microbiota of individual humans confirmed the broad applicability of this strategy.